Mycoplasma pneumoniae pneumonia

Summary

Mycoplasma pneumoniae pneumonia (MONDO:0005867) is a disease and 9 clinical trials. Top therapeutic interventions include doxycycline anhydrous, levofloxacin anhydrous, and ofloxacin. A subtype of bacterial pneumonia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Mycoplasma pneumoniae pneumonia
Mondo ID	MONDO:0005867
EFO	EFO:0007387
MeSH	D011019
DOID	DOID:13276
ICD-10-CM	J15.7
NCIT	C122526
SNOMED CT	46970008
UMLS	C0032302
MedGen	19363
GARD	0007125
Is cancer (heuristic)	no

Also known as: Mycoplasmal pneumonia · pneumonia due to Mycoplasma pneumoniae

Disease family

This is a subtype of bacterial pneumonia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › bacterial pneumonia › Mycoplasma pneumoniae pneumonia

Related subtypes (7): anaerobic pneumonia, Legionnaires’ disease, staphylococcal pneumonia, streptococcal pneumonia, Klebsiella pneumonia, pneumonia caused by pseudomonas aeruginosa infection, pneumonia caused by gram negative bacteria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07306234	PHASE4	NOT_YET_RECRUITING	Doxycycline vs. Macrolide for MRMP (DOMINO)
NCT02618057	PHASE4	UNKNOWN	Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia
NCT06325293	Not specified	RECRUITING	A Trial of Placebo Versus Macrolide for Mycoplasma Pneumoniae Childhood Pneumonia: MYTHIC Study
NCT01217099	Not specified	TERMINATED	Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children
NCT02303587	Not specified	COMPLETED	Methylprednisolone for Children With Severe Mycoplasma Pneumoniae Pneumonia (MCMP)
NCT04296383	Not specified	UNKNOWN	Xiyanping Injection Combined With Azithromycin VS Azithromycin for Children With pneumoniaProtozoal Pneumonia
NCT06348095	Not specified	COMPLETED	Effect of Probiotics on Mycoplasma Pneumoniae Pneumonia
NCT07064278	Not specified	COMPLETED	Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children
NCT07333833	Not specified	COMPLETED	Development and Validation of an Early Prediction Model for Severe Mycoplasma Pneumoniae Pneumonia in Children

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DOXYCYCLINE ANHYDROUS	4	3
LEVOFLOXACIN ANHYDROUS	4	2
OFLOXACIN	4	1
PREDNISOLONE	4	1